Dave Humphrey Email & Phone Number

La Jolla, California, Us

Clinical-stage biotechnology company using proprietary technology platforms to develop safer prescription drugs. Developing new class of tamper-proof opioids that prevent both drug abuse and overdose. • Led transition to a public company with Nasdaq listing through merger with a special purpose acquisition company (SPAC) in June 2021 providing cash proceeds of $8 million. • Drive ongoing financing efforts resulting in a variety of successful transactions: - Convertible debt offerings of $15 million in Sept '21, $8 million in June '22 and $2 million in Oct '23. - Public offerings of stock and warrants for $4 million in December 2022 and $7 million in May 2023. - Registered direct offering of common stock and warrants for $3 million in February 2023.• Guide investor relations through investor presentations, quarterly earnings calls and communications with analysts and key investors.• Established administrative infrastructure with implementation of HR and IT systems for payroll, insurance benefits, 401k plan, stock plan administration and Microsoft 365.

• As part of core executive management team, I advised the board of directors during an extensive strategic review process resulting in a $75 million acquisition by Firmenich, a private Swiss multinational flavor and fragrance company. I coordinated with multiple investment bankers, developed long-range financial models and addressed financial due diligence requests from multiple suitors, while also advising on negotiation strategy and merger terms and conditions.• I guided the company through a period of cash concerns with increased focus on forecasting, budgeting and spending which yielded expense reductions of $3.8 million or 11% compared to prior periods.

• I created program valuation models and analyzed a range of possible alternatives for the board of directors during an asset divestiture process that yielded $10 million of critical, non-dilutive funding.• I directed investor relations efforts in conducting quarterly earnings calls, determining financial guidance, developing investor conference presentations and maintaining communications with analysts and investors.

• I prepared financial due diligence, co-developed corporate presentation and coordinated with investment bankers for public financing efforts and with an investor group for $14 million equity financing vehicle.• I managed multiple administrative functions covering finance, accounting, cash management, stock administration, payroll and purchasing.

• I directed public company financial reporting, including Forms 10-K, 10-Q, 8-K, S-3, S-8, proxy statements and SOX internal controls compliance, acting as primary liaison with Audit Committee and external auditors.

Based on my interest in personal finance, I founded a fee-only personal financial planning firm providing integrated financial advice to individuals, families and small business owners. I analyzed client finances and designed a customized strategy based upon current financial situation, goals and risk tolerance. I monitored and adapted client financial plans to changing needs and circumstances. As sole proprietor, I managed all aspects of a small business, including client service, marketing, business development, information technology and regulatory compliance.

I consulted at the controller level for multiple biotechnology and medical device companies, including Senomyx, LMA North America and Akesis Pharmaceuticals. • Projects included S-1 filing for IPO, monthly financial reporting, 10-K and annual audit preparation, Sarbanes-Oxley assessment, stock administration, income tax provisions and consolidations.

La Jolla, Ca, Us

I established financial operations for a growing start-up biotechnology company, collaborating with the executive team and Board of Directors to develop the business and financing strategy. • Managed relationships with investment bankers and venture capitalists, completing a $20 million venture capital financing round that included four new investors. • Developed financial infrastructure, including accounting controls, policies and procedures. • Directed accounting, purchasing, treasury, insurance and stock administration functions.

I managed the accounting operations, including staff of eight, for a growing public company with biotechnology and instrumentation manufacturing operations.• Provided operational forecasts, planning and analysis for company managers.• Implemented and managed financial components of enterprise-wide Oracle Applications ERP system.• Performed financial due diligence and integration of multiple mergers and acquisitions. • Completed financial reporting for $71 million private equity investment and $86 million acquisition. • Coordinated audits and prepared financial disclosures for Nasdaq initial public offering (IPO).

I led the accounting operations for the worldwide corporate headquarters as well as the biotechnology and medical device divisions. • Prepared and analyzed financial statements for external reporting and management review.• Created financial models for both short-term operational forecasting and long-term strategic planning, including extensive mergers and acquisitions analysis for a $150 million international acquisition.

Gb

I planned, coordinated and monitored independent audits, as well as trained, supervised and evaluated performance of staff accountants. I evaluated client accounting systems and resolved significant accounting issues.